Virginia Retirement Systems’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$932K Buy
21,400
+14,800
+224% +$528K 0.01% 527
2023
Q2
$238K Buy
+6,600
New +$272K ﹤0.01% 894
2022
Q4
Sell
-6,800
Closed -$475K 1260
2022
Q3
$475K Buy
+6,800
New +$503K 0.01% 810
2022
Q1
$247K Sell
3,000
-1,000
-25% -$102K ﹤0.01% 1022
2021
Q4
$587 Buy
+4,000
New +$621K ﹤0.01% 804
2021
Q3
Sell
-3,000
Closed -$485K 1104
2021
Q2
$485K Sell
3,000
-500
-14% -$80.3K ﹤0.01% 834
2021
Q1
$600K Buy
3,500
+500
+17% +$99K 0.01% 829
2020
Q4
$659K Sell
3,000
-400
-12% -$86.5K 0.01% 754
2020
Q3
$565K Sell
3,400
-1,300
-28% -$178K 0.01% 722
2020
Q2
$537K Sell
4,700
-300
-6% -$29.1K 0.01% 769
2020
Q1
$384K Buy
+5,000
New +$448K 0.01% 874

Other funds holding MRTX

Virginia Retirement Systems's MRTX Position: Q3 2023 in Review

Virginia Retirement Systems increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 224% in Q3 2023, buying an estimated $528K and bringing the position to 21,400 shares worth $932K. The position accounts for 0.01% of the portfolio, ranked #527.

Virginia Retirement Systems first reported a position in MRTX in Q1 2020 and has held it in 11 quarters since. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • Virginia Retirement Systems held 21,400 shares of Mirati Therapeutics, Inc. Common Stock worth $932K as of Q3 2023.
  • Virginia Retirement Systems bought 14,800 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $528K.
  • Mirati Therapeutics, Inc. Common Stock made up 0.01% of Virginia Retirement Systems's portfolio in Q3 2023, its #527 holding.
  • Virginia Retirement Systems first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and has held it in 11 quarters since.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Virginia Retirement Systems's 13F filing for Q3 2023, filed 2 Jan 2024.